Peat Therapy for Psoriasis — What the Evidence Shows

Psoriasis affects 2–3% of the global population. It is a chronic autoimmune condition — not a surface problem but an immune system malfunction that causes the skin to generate new cells at five to ten times the normal rate, producing the characteristic thick, scaly plaques. There is no cure. Management means reducing inflammation, slowing cell turnover, and relieving itch for as long as possible before a flare.

Peat therapy has been used for psoriasis in Central European spa medicine for over a century. The question is not whether it has a tradition — it does. The question is what the evidence actually shows, and why the biology is plausible.

Why Peat Is Biologically Relevant to Psoriasis

Psoriasis is driven primarily by the TNF-α and IL-17/IL-23 inflammatory axes. Plaques form when keratinocytes receive inflammatory signals and respond by proliferating uncontrollably, while immune cells flood the dermis and epidermis.

Peat addresses this pathology through three simultaneous mechanisms:

Anti-inflammatory. Humic acids — the primary bioactive fraction of peat, comprising 10–40% of its dry mass — inhibit TNF-α production in a dose-dependent manner. At concentrations above 100 μg/ml, humic acids reduce TNF-α by up to tenfold in vitro (Junek et al., 2009, cited in Übner 2013). Verrillo et al. (2022) demonstrated that lignite-derived humic acids significantly decreased IL-6 and IL-1β gene expression in human keratinocytes — both cytokines directly implicated in psoriatic inflammation.

Keratolytic. Humic substances soften and help dissolve the bonds between dead keratinocytes, reducing plaque buildup without the irritation associated with pharmaceutical keratolytics such as salicylic acid. This is particularly relevant for psoriasis palmaris (palm and sole plaques) where thick scale accumulation is the primary complaint.

Immunomodulatory. Tolpa Peat Preparation (TPP) — a standardized humic acid extract derived from peat, and the only peat-derived substance to achieve pharmaceutical registration — was registered in Poland as an immunomodulator. It induces interferon-α, interferon-γ, and TNF-α production at low concentrations while suppressing them at higher concentrations, suggesting a regulatory rather than simply suppressive effect (Übner 2013).

What the Clinical Evidence Shows

Balneotherapy (peat baths) has the strongest evidence base. Jazani et al. (2022) conducted a systematic review confirming balneotherapy efficacy for psoriasis, drawing on multiple cohort studies from Czech, Hungarian, and German spa clinics. Wollina (2009) — a German dermatology review — reported that daily peat application in psoriasis palmaris produced rapid itch relief, decreased inflammation, and earlier resolution of pustules compared to topical corticosteroid monotherapy. PASI (Psoriasis Area and Severity Index) score improvements after 2–3 week treatment courses of daily peat baths are consistently reported across the literature.

Mud packs applied directly to plaques deliver concentrated bioactive material to the affected area. Khan et al. (2023) demonstrated that a fulvic acid nanoemulsion gel ameliorated IMQ-induced psoriasis in mice by targeting IL-6 and TNF-α — a mechanism that applies to topical peat formats as well.

Scalp treatments address scalp psoriasis. Bovcon et al. (2012) showed that peat shampoo reduced scalp squames and improved scalp health through mechanisms directly relevant to scalp psoriasis — anti-inflammatory and keratolytic activity combined with pH normalization.

The honest assessment: most evidence is cohort-level or clinical observation. Large randomized controlled trials are limited — partly because peat therapy is difficult to blind (you know whether you’re in a peat bath), and partly because research funding has concentrated on pharmaceutical rather than balneological interventions. Beer et al. (2013) notes this gap in their German review of peloid therapy for dermatological conditions.

Evidence Grade by Application

Practical Context

Peat therapy for psoriasis is not a replacement for medical treatment. Biologics, phototherapy, and topical corticosteroids have a stronger evidence base for severe or widespread disease. Peat therapy is best understood as an adjunctive approach — most useful for mild-to-moderate plaque psoriasis, palmar-plantar psoriasis, and scalp involvement, and most commonly used within a structured balneological course (10–21 daily sessions) at a spa clinic.

The thermal component of peat baths enhances the effect. Peat retains heat significantly longer than plain water — losing less than 1°C over 20 minutes (Korhonen 2008) — which sustains cutaneous vasodilation, improves drug penetration, and provides the muscle relaxation that reduces the stress-mediated component of psoriatic flares.

For home use, peat-derived cosmetics (creams, scalp treatments, bath additives) provide lower-dose, chronic exposure to the same bioactive compounds. The evidence for clinical-grade outcomes from home products is weaker, but the mechanistic rationale — sustained low-dose anti-inflammatory and keratolytic exposure — is sound.

The Bottom Line

Peat therapy for psoriasis has a plausible biological basis and a reasonable body of clinical evidence — stronger than most natural interventions, weaker than established pharmaceuticals. The anti-inflammatory, keratolytic, and immunomodulatory properties of humic substances address the core pathology of psoriasis through different pathways than corticosteroids or biologics, which is why combination approaches are the norm in integrative dermatology clinics in Central Europe.